A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(−2) and EPI 45 mg m(−2). Median time to progression was 5.1 months and median survival time 7.4 months. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eickhoff, A, Martin, W, Hartmann, D, Eickhoff, J C, Möhler, M, Galle, P R, Riemann, J F, Jakobs, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361302/
https://www.ncbi.nlm.nih.gov/pubmed/16721369
http://dx.doi.org/10.1038/sj.bjc.6603174
_version_ 1782153183002361856
author Eickhoff, A
Martin, W
Hartmann, D
Eickhoff, J C
Möhler, M
Galle, P R
Riemann, J F
Jakobs, R
author_facet Eickhoff, A
Martin, W
Hartmann, D
Eickhoff, J C
Möhler, M
Galle, P R
Riemann, J F
Jakobs, R
author_sort Eickhoff, A
collection PubMed
description Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(−2) and EPI 45 mg m(−2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.
format Text
id pubmed-2361302
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23613022009-09-10 A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma Eickhoff, A Martin, W Hartmann, D Eickhoff, J C Möhler, M Galle, P R Riemann, J F Jakobs, R Br J Cancer Short Communication Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(−2) and EPI 45 mg m(−2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity. Nature Publishing Group 2006-06-05 2006-05-23 /pmc/articles/PMC2361302/ /pubmed/16721369 http://dx.doi.org/10.1038/sj.bjc.6603174 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Eickhoff, A
Martin, W
Hartmann, D
Eickhoff, J C
Möhler, M
Galle, P R
Riemann, J F
Jakobs, R
A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
title A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
title_full A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
title_fullStr A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
title_full_unstemmed A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
title_short A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
title_sort phase i/ii multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361302/
https://www.ncbi.nlm.nih.gov/pubmed/16721369
http://dx.doi.org/10.1038/sj.bjc.6603174
work_keys_str_mv AT eickhoffa aphaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT martinw aphaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT hartmannd aphaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT eickhoffjc aphaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT mohlerm aphaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT gallepr aphaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT riemannjf aphaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT jakobsr aphaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT eickhoffa phaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT martinw phaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT hartmannd phaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT eickhoffjc phaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT mohlerm phaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT gallepr phaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT riemannjf phaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma
AT jakobsr phaseiiimulticentrictrialofgemcitabineandepirubicininpatientswithadvancedpancreaticcarcinoma

Ejemplares similares